2492:TWSEWalsin Technology Corporation Analysis
Data as of 2026-06-17 - not real-time
NT$542.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Walsin Technology Corp (2492.TW) is trading at TWD 542, matching its 52‑week high and well above the computed DCF fair value of ~TWD 116. The stock sits above its 20‑day SMA (400.8) and 50‑day SMA (255.2), confirming a strong bullish momentum, while the MACD line (66.46) remains above its signal (61.83) and the histogram is positive. However, the RSI of 78 places the equity in the overbought zone, and volume trends are decreasing, suggesting waning buying pressure. The price is hugging the identified resistance level (542) and only modestly above the support (259.5), implying limited upside without a breakout. Valuation metrics are extreme: a trailing PE of 114 versus an industry average of 37, and a price‑to‑book of 8.3, indicating the market is pricing in far‑greater growth than current fundamentals support.
Fundamentally, revenue grew 9 % YoY to TWD 37.3 bn, yet margins are thin (gross 17.6 %, operating 7.5 %) and ROE is just 5.2 %. The balance sheet shows a high debt load (TWD 29.3 bn) with a debt‑to‑equity of 45, and cash of TWD 14.3 bn, yielding a modest net leverage. Cash flow is positive but free cash flow is limited relative to earnings. The combination of high volatility (≈98 % over 30 days), a beta near 1, and a recent max drawdown of 27 % underscores a volatile risk profile. With no dividend and an extreme greed market sentiment (fear‑greed index 88.5), the stock appears overvalued and vulnerable to a correction.
Fundamentally, revenue grew 9 % YoY to TWD 37.3 bn, yet margins are thin (gross 17.6 %, operating 7.5 %) and ROE is just 5.2 %. The balance sheet shows a high debt load (TWD 29.3 bn) with a debt‑to‑equity of 45, and cash of TWD 14.3 bn, yielding a modest net leverage. Cash flow is positive but free cash flow is limited relative to earnings. The combination of high volatility (≈98 % over 30 days), a beta near 1, and a recent max drawdown of 27 % underscores a volatile risk profile. With no dividend and an extreme greed market sentiment (fear‑greed index 88.5), the stock appears overvalued and vulnerable to a correction.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price at 52‑week high and resistance level
- RSI in overbought territory
- Decreasing volume trend
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Extreme PE relative to industry
- Thin profit margins and modest ROE
- High volatility and recent drawdown
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- DCF fair value far below market price
- Heavy debt load and low dividend yield
- Potential correction driven by overvaluation
Key Metrics & Analysis
Financial Health
Revenue Growth9.10%
Profit Margin6.80%
P/E Ratio114.3
ROE5.21%
ROA1.42%
Debt/Equity45.46
P/B Ratio8.3
Op. Cash FlowNT$5.5B
Free Cash FlowNT$3.6B
Industry P/E37.0
Technical Analysis
TrendBullish
RSI77.7
SupportNT$259.50
ResistanceNT$542.00
MA 20NT$400.80
MA 50NT$255.24
MA 200NT$151.30
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair ValueNT$115.75
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.97
Volatility98.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.